55 results on '"Mazumder, Amitabha"'
Search Results
2. Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma
3. Identification of Agents That Promote Endoplasmic Reticulum Stress Using an Assay That Monitors Luciferase Secretion
4. Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients
5. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
6. Risk Stratification of Plasma Cell Neoplasm: Insights From Plasma Cell–Specific Cytoplasmic Immunoglobulin Fluorescence in Situ Hybridization (cIg FISH) vs. Conventional FISH
7. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
8. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
9. HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis
10. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
11. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
12. HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients
13. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma
14. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
15. Hydroxychloroquine for the treatment of chronic graft-versus-host disease
16. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis
17. The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone
18. Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population
19. HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
20. Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
21. Intracranial Multifocal Dural Involvement in Multiple Myeloma: Case Report and Review of the Literature
22. Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: A Case Series Illustrating Utility in Clinical Practice
23. Cell Line-Dependent Synergy Between the PARP Inhibitor Veliparib and the Proteasome Inhibitor Bortezomib in the Killing of Myeloma Cells
24. Targeting Plasticity and Stemness in Multiple Myeloma Tumor Cells
25. CD138 Regulates Myeloma Cell Survival, Proliferation, BM Engraftment and Tumor Organization
26. Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions
27. Netrin-1 Promotes Osteoclast Activity in Multiple Myeloma Under Hypoxic Conditions: Modulation By a RANKL Inhibitor
28. A Phase II Trial of Chloroquine in Combination with Bortezomib and Cyclophosphamide in Patients with Relapsed and Refractory Multiple Myeloma
29. A Phase II Trial of TBL12 Sea Cucumber Extract in Patients with Untreated Asymptomatic Myeloma
30. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
31. Plasmacytoma in the Breast with Axillary Lymph Node Involvement: A Case Report
32. PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma
33. Ex Vivo Patient-Specific Validation Of Personalized Therapeutic Designed For Multiple Myeloma
34. Predictive Simulation Based Design and Validation Of Repurposed Novel Therapeutics With Multi-Target Mechanisms For Multiple Myeloma
35. Bone Marrow Stromal Mediated Pro-Oncogenic Wnt/β-Catenin Antagonize sDKK1 and Promote Osteoclast Activity In Multiple Myeloma
36. PROGNOSTIC ROLE OF AL AMYLOID DEPOSITION IN VASCULATURE
37. MAGE-A3 Specific T-Cell Receptor Adoptive Cell Transfer of Multiple Myeloma
38. Detection of Multiple Myeloma Cells in Peripheral Blood Using High-Throughput Sequencing Assay
39. A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients with Untreated Asymptomatic Myeloma,
40. Treatment of Multiple Myeloma with Vorinostat in Combination with Bortezomib: A Case Series
41. Successful Salvage and Hematopoietic Reconstitution with Bortezomib and Melphalan in Relapsed and Refractory Multiple Myeloma
42. Ritonavir Sensitizes Multiple Myeloma Cells to Bortezomib-Induced Apoptosis
43. Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.
44. Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
45. A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
46. Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.
47. Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.
48. Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma.
49. A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
50. Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.